MedPath

Whole Brain Radiotherapy following local treatment of melanoma brain metastases

Phase 3
Completed
Conditions
Melanoma brain metastases
Cancer - Malignant melanoma
Registration Number
ACTRN12607000512426
Lead Sponsor
Melanoma and Skin Cancer (MASC) Trials
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
215
Inclusion Criteria

1. 1-3 intracranial metastases on MRI from melanoma, locally treated with either surgical excision and/or stereotactic irradiation. 2. Life expectancy of at least 6 months 3. Aged 18 years or older 4. WBRT must be within 8 weeks of completion of localised treatment and within 4 weeks of randomisation 5. Able to have an MRI brain scan with contrast. ‘estimated Glomerular Filtrate Rate’ (eGFR) is adequate at the discretion of the radiologist and capable of having gadolinium-containing contrast medium for MRI as per practice guidelines 6. Complete localised treatment of all these metastases no more than 6 weeks prior to randomisation 7. An Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less at randomisation 8. CT scan of chest, abdomen and pelvis as a minimum prior to randomisation. Scans must be within 12 weeks of randomisation 9. Serum Lactate Dehydrogenase (LDH) must be = or < 2 x upper limit of normal 10. Able to provide written informed consent

Exclusion Criteria

1.Any untreated intracranial disease
2.Any previous intracranial treatment (surgical excision and/or stereotactic irradiation treatment and/or WBRT) prior to this diagnosis of intracranial melanoma
3.Evidence of leptomeningeal disease on pre-local treatment MRI scan
4.Patients with prior cancers, except:
oThose diagnosed more than five years ago with no evidence of disease recurrence within this time;
oSuccessfully treated basal cell and squamous cell skin carcinoma;
oCarcinoma in-situ of the cervix
5.A medical or psychiatric condition that compromises ability to give informed consent or complete the protocol
6.Positive urine pregnancy test for women of childbearing potential within a week of registration onto the trial

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Proportion of patients with distant intracranial failure as determined by magnetic resonance imaging (MRI) assessment[ 12 months post randomisation]
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath